(258) Public health impact of increasing RSV vaccination uptake among US adults aged ≥60 years: A modeling analysis based on real-world uptake data through February 2025

Background: : In 2023, respiratory syncytial virus (RSV) vaccination was first recommended by the Advisory Committee on Immunization Practices among adults aged ≥60 years in the United States (US). Based on claims data analyses through February 2025, only 16.4% of US adults aged ≥60 years had received an RSV vaccination.

Objective: : This analysis modeled the public health impact of increasing RSV vaccination uptake among US adults aged ≥60 years.

Methods: : A multicohort Markov model estimated RSV-related cases, healthcare resource use, and deaths with and without adjuvanted RSVPreF3 vaccination of US adults aged ≥60 years. Vaccination uptake was based on age-specific cumulative uptake between August 2023-February 2025 (ranging from 8.1% for adults aged 60–64 years to 23.3% for adults aged 75–79 years). As a simplifying assumption, vaccination with adjuvanted RSVPreF3 was modeled to occur in August 2023. Other inputs were based on clinical trial data and a targeted review of literature and public sources. Avoided RSV disease burden was estimated for the 5-year period between August 2023–July 2028. In addition to modeling actual RSV vaccination uptake in the base case, two scenarios of increased uptake were assessed: assuming all age groups achieved the highest uptake observed for 75–79-year-olds (23.3%) and assuming a 5 percentage-point increase in uptake for all age groups.

Results: : Using actual age-specific RSV vaccination uptake, the model estimated that 13.4 million US adults aged ≥60 years were vaccinated through February 2025. Assuming vaccination in August 2023, these vaccinations resulted in an estimated 714,362 fewer RSV lower respiratory tract disease (LRTD) cases, 74,082 fewer hospitalizations, and 6,025 fewer deaths over 5 years versus no vaccination. If all age groups would have achieved the highest-observed uptake of 23.3%, an additional 5.8 million adults would have been vaccinated. These vaccinations would have resulted in an additional 319,771 RSV-LRTD cases averted, 21,411 hospitalizations averted, and 1,589 deaths averted over 5 years versus the base case. A 5 percentage-point increase from the base case uptake would have resulted in an additional 4.1 million vaccinations versus the base case, avoiding an additional 222,145 RSV-LRTD cases, 20,513 hospitalizations, and 1,636 deaths over 5 years.

Conclusions: : Results highlight the substantial RSV disease burden that is already being avoided by RSV vaccination. Even relatively small increases in RSV vaccination uptake may result in further measurable public health benefits.

Sponsorship:: GSK VEO-001295